Wire Stories
939Samsung Announces New NAND Flash Facility to Address Future Data Center and Mobile Demands
Located inside Pyeongtaek’s Line 2 in Korea, the new facility is slated for mass production in 2H 2021 The facility will be...
- 974
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load of SARS-CoV-2 (COVID-19), as well as improvement...
- 794
YouTube Entrepreneur Matt Par to Host a Free Training Webinar That Will Help Millennials Monetize Their Channels
SAN FRANCISCO–(BUSINESS WIRE)–19-year-old YouTube expert Matt Par has created a free training webinar for wannabe content creators looking to get started on...
- 821
Global Leading Institutions Took Stakes in Yeahka, Showing Confidence in Its Long-Term Prospects
HONG KONG–(BUSINESS WIRE)–YEAHKA LIMITED, China’s leading payment and business service technology platform commences trading on the Main Board of The Stock Exchange...
- 761
ViaBTC Group Announces Strategic Upgrade to Advance Innovation and Improve Customer Experience
HONG KONG–(BUSINESS WIRE)–ViaBTC Group, an innovative technology company specialized in blockchain and dedicated to providing users with comprehensive digital asset management services,...
- 777
Crash Barrier Systems Market 2020-2024 | Implementation of Road Safety Programs to Boost Market Growth | Technavio
LONDON–(BUSINESS WIRE)–#CrashBarrierSystemsMarket–The crash barrier systems market is expected to grow by USD 1.29 billion during 2020-2024. The report also provides the market...
- 1.2K
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
61.9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently...
- 1.1K
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
TOKYO & BASKING RIDGE, N.J. & MUNICH–(BUSINESS WIRE)–Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)...
- 888
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation is designed...
- 771
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a...
